Henri Janicot

2.7k total citations
32 papers, 658 citations indexed

About

Henri Janicot is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Henri Janicot has authored 32 papers receiving a total of 658 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in Henri Janicot's work include Lung Cancer Research Studies (18 papers), Lung Cancer Treatments and Mutations (15 papers) and Lung Cancer Diagnosis and Treatment (7 papers). Henri Janicot is often cited by papers focused on Lung Cancer Research Studies (18 papers), Lung Cancer Treatments and Mutations (15 papers) and Lung Cancer Diagnosis and Treatment (7 papers). Henri Janicot collaborates with scholars based in France, Luxembourg and Canada. Henri Janicot's co-authors include C. Chouaïd, Florian Guisier, Radj Gervais, Catherine Dubos‐Arvis, R. Lamy, M. Pérol, P. Fournel, H. Doubre, Olivier Bylicki and Stanislas Ropert and has published in prestigious journals such as Journal of Clinical Oncology, American Journal of Respiratory and Critical Care Medicine and Clinical Cancer Research.

In The Last Decade

Henri Janicot

31 papers receiving 644 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Henri Janicot France	12	482	464	162	129	68	32	658
Feiyu Niu China	12	266 0.6×	314 0.7×	175 1.1×	79 0.6×	130 1.9×	25	513
Yoshitaka Zenke Japan	12	408 0.8×	339 0.7×	259 1.6×	62 0.5×	85 1.3×	79	644
Pamela Biondani Italy	12	341 0.7×	162 0.3×	104 0.6×	92 0.7×	79 1.2×	37	505
Eisaku Miyauchi Japan	13	355 0.7×	344 0.7×	239 1.5×	52 0.4×	235 3.5×	66	691
Cuiling Zhou China	10	253 0.5×	143 0.3×	104 0.6×	119 0.9×	48 0.7×	11	404
J.B. Auliac France	15	433 0.9×	604 1.3×	121 0.7×	35 0.3×	161 2.4×	64	741
Kaiqi Du China	14	227 0.5×	274 0.6×	162 1.0×	30 0.2×	100 1.5×	35	438
Brenda Dickow United States	11	215 0.4×	280 0.6×	162 1.0×	41 0.3×	94 1.4×	20	449
Jorge Alatorre-Alexander Mexico	7	785 1.6×	349 0.8×	179 1.1×	339 2.6×	56 0.8×	25	880
Cláudia Casanova Italy	9	273 0.6×	267 0.6×	100 0.6×	50 0.4×	128 1.9×	24	421

Countries citing papers authored by Henri Janicot

Since Specialization

Citations

This map shows the geographic impact of Henri Janicot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henri Janicot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henri Janicot more than expected).

Fields of papers citing papers by Henri Janicot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henri Janicot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henri Janicot. The network helps show where Henri Janicot may publish in the future.

Co-authorship network of co-authors of Henri Janicot

This figure shows the co-authorship network connecting the top 25 collaborators of Henri Janicot. A scholar is included among the top collaborators of Henri Janicot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henri Janicot. Henri Janicot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dall’Olio, Filippo Gustavo, Bastien Job, Stefan Michiels, et al.. (2024). Genomic instability in advanced non-small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIR02-Lung/ IFCT1301 trial.. Journal of Clinical Oncology. 42(16_suppl). 2632–2632. 1 indexed citations

Pereira, Bruno, et al.. (2023). Oligroprogression sous nivolumab du cancer bronchique non à petites cellules métastatiques traitées par radiothérapie. Bulletin du Cancer. 110(12). 1234–1243. 1 indexed citations

Dall’Olio, Filippo Gustavo, Damien Vasseur, Maryam Karimi, et al.. (2023). Association of ctDNA tumor fraction with survival in advanced non-small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIR02-Lung/IFCT1301 trial.. Journal of Clinical Oncology. 41(16_suppl). 2516–2516.

Wislez, Marie, Charlotte Domblides, Laurent Greillier, et al.. (2021). Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA). Lung Cancer. 157. 124–130. 5 indexed citations

Lavolé, A., Laurent Greillier, Julien Mazières, et al.. (2020). First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial. European Respiratory Journal. 56(2). 1902066–1902066. 7 indexed citations

Bylicki, Olivier, Florian Guisier, I. Monnet, et al.. (2020). Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma. Medicine. 99(3). e18726–e18726. 22 indexed citations

Guisier, Florian, Catherine Dubos‐Arvis, F. Viñas, et al.. (2020). Efficacy and Safety of Anti–PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018. Journal of Thoracic Oncology. 15(4). 628–636. 215 indexed citations

Eberst, Guillaume, Amélie Anota, Arnaud Scherpereel, et al.. (2019). Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial. Clinical Cancer Research. 25(19). 5759–5765. 15 indexed citations

Baize, Nathalie, I. Monnet, Laurent Greillier, et al.. (2019). OA15.02 Carboplatin-Etoposide Versus Topotecan as Second-Line Treatment for Sensitive Relapsed Small-Cell Lung Cancer: Phase 3 Trial. Journal of Thoracic Oncology. 14(10). S246–S246. 5 indexed citations

10.

Christodoulou, Maria, Fiona Blackhall, Hitesh Mistry, et al.. (2018). Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial. Journal of Thoracic Oncology. 14(1). 63–71. 25 indexed citations

11.

Auliac, J.B., G François, Henri Janicot, et al.. (2018). Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors. Targeted Oncology. 13(4). 501–507. 35 indexed citations

12.

Westeel, Virginie, Guillaume Eberst, Amélie Anota, et al.. (2018). Impact on health-related quality of life of the addition of bevacizumab to cisplatin-pemetrexed in malignant pleural mesothelioma in the MAPS phase III trial.. Journal of Clinical Oncology. 36(15_suppl). 8505–8505. 2 indexed citations

13.

Radosevic‐Robin, Nina, Sarah Warren, Myriam Kossaï, et al.. (2018). Gene expression (GE)-based biomarkers associated with nivolumab response in a real-life cohort of patients with metastatic non-small cell lung cancer (mNSCLC). Annals of Oncology. 29. viii38–viii39. 1 indexed citations

14.

Christodoulou, Maria, Fiona Blackhall, Linda Ashcroft, et al.. (2017). OA05.06 Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily versus Twice-Daily RadioTherapy (CONVERT) Trial. Journal of Thoracic Oncology. 12(1). S262–S263. 1 indexed citations

15.

Jeannin, G., P. Merle, Henri Janicot, et al.. (2015). Combined treatment modalities in Pancoast tumor: results of a monocentric retrospective study.. PubMed. 4(4). 39–39. 5 indexed citations

16.

Pujol, Jean Louis, Radj Gervais, Marie‐Laure Tanguy, et al.. (2007). Phase III Double-Blind, Placebo-Controlled Study of Thalidomide in Extensive-Disease Small-Cell Lung Cancer After Response to Chemotherapy: An Intergroup Study FNCLCC cleo04–IFCT 00-01. Journal of Clinical Oncology. 25(25). 3945–3951. 97 indexed citations

17.

Pujol, Jean-Louis, Jean-Luc Breton, R. Gervais, et al.. (2005). Gemcitabine–docetaxel versus cisplatin–vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Annals of Oncology. 16(4). 602–610. 101 indexed citations

18.

Aumaître, O., M. André, Jean‐Louis Kémény, et al.. (1999). Apport de la tomodensitométrie dans le suivi évolutif des lésions pleuropulmonaires de la granulomatose de Wegener. La Revue de Médecine Interne. 20(7). 571–578. 5 indexed citations

19.

Bedu, M., et al.. (1996). Interaction Between Cold and Hypoxia on Pulmonary Circulation in COPD. American Journal of Respiratory and Critical Care Medicine. 153(4). 1242–1247. 8 indexed citations

20.

Depierre, A, B. Milleron, D Moro, et al.. (1995). 1053 Phase III study of neo-adjuvant chemotherapy in resectable non-small cell lung cancer (NSCLC). European Journal of Cancer. 31. S220–S220. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact